Kala Pharmaceuticals Stock Price, News & Analysis (NASDAQ:KALA)

$4.58
+0.03 (+0.66 %)
(As of 09/20/2019 02:33 PM ET)
Today's Range
$4.46
Now: $4.58
$4.61
50-Day Range
$3.62
MA: $4.38
$6.0953
52-Week Range
$3.50
Now: $4.58
$11.09
Volume7,531 shs
Average Volume264,606 shs
Market Capitalization$155.77 million
P/E RatioN/A
Dividend YieldN/A
Beta2.15
Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KALA
CUSIPN/A
Phone781-996-5252

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$3.11 per share

Profitability

Net Income$-66,740,000.00

Miscellaneous

Employees130
Market Cap$155.77 million
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable

Receive KALA News and Ratings via Email

Sign-up to receive the latest news and ratings for KALA and its competitors with MarketBeat's FREE daily newsletter.


Kala Pharmaceuticals (NASDAQ:KALA) Frequently Asked Questions

What is Kala Pharmaceuticals' stock symbol?

Kala Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALA."

How were Kala Pharmaceuticals' earnings last quarter?

Kala Pharmaceuticals Inc (NASDAQ:KALA) released its quarterly earnings data on Tuesday, August, 6th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.74) by $0.04. The company had revenue of $2.06 million for the quarter, compared to the consensus estimate of $2.62 million. View Kala Pharmaceuticals' Earnings History.

When is Kala Pharmaceuticals' next earnings date?

Kala Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, November 14th 2019. View Earnings Estimates for Kala Pharmaceuticals.

What price target have analysts set for KALA?

6 analysts have issued 1 year price objectives for Kala Pharmaceuticals' stock. Their forecasts range from $9.00 to $51.00. On average, they anticipate Kala Pharmaceuticals' share price to reach $20.6667 in the next twelve months. This suggests a possible upside of 351.2% from the stock's current price. View Analyst Price Targets for Kala Pharmaceuticals.

What is the consensus analysts' recommendation for Kala Pharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kala Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kala Pharmaceuticals.

Has Kala Pharmaceuticals been receiving favorable news coverage?

News coverage about KALA stock has been trending negative this week, according to InfoTrie Sentiment. The research firm identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Kala Pharmaceuticals earned a media sentiment score of -2.9 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the next few days. View News Stories for Kala Pharmaceuticals.

Who are some of Kala Pharmaceuticals' key competitors?

What other stocks do shareholders of Kala Pharmaceuticals own?

Who are Kala Pharmaceuticals' key executives?

Kala Pharmaceuticals' management team includes the folowing people:
  • Mr. Mark T. Iwicki, Chairman, Pres & CEO (Age 53)
  • Mr. Todd Bazemore, Chief Operating Officer (Age 49)
  • Dr. Kim Brazzell, Chief Medical Officer (Age 66)
  • Dr. Justin Hanes Ph.D., Founder & Chair of the Scientific Advisory Board
  • Ms. Mary Reumuth CPA, CPA, CFO & Treasurer (Age 44)

When did Kala Pharmaceuticals IPO?

(KALA) raised $90 million in an IPO on Thursday, July 20th 2017. The company issued 6,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Wells Fargo Securities and Wedbush PacGrow were co-managers.

Who are Kala Pharmaceuticals' major shareholders?

Kala Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (4.95%), Vanguard Group Inc. (3.64%), Sofinnova Investments Inc. (0.87%), JPMorgan Chase & Co. (0.76%), Price T Rowe Associates Inc. MD (0.73%) and Northern Trust Corp (0.58%). Company insiders that own Kala Pharmaceuticals stock include Gregory Grunberg, Howard B Rosen, Orbimed Advisors Llc and Ra Capital Healthcare Fund Lp. View Institutional Ownership Trends for Kala Pharmaceuticals.

Which major investors are selling Kala Pharmaceuticals stock?

KALA stock was sold by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Wedbush Securities Inc., Sofinnova Investments Inc., Price T Rowe Associates Inc. MD, JPMorgan Chase & Co. and Wells Fargo & Company MN. View Insider Buying and Selling for Kala Pharmaceuticals.

Which major investors are buying Kala Pharmaceuticals stock?

KALA stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., Boston Partners, Alambic Investment Management L.P., Bank of New York Mellon Corp, Charles Schwab Investment Management Inc., Northern Trust Corp and Parametric Portfolio Associates LLC. Company insiders that have bought Kala Pharmaceuticals stock in the last two years include Gregory Grunberg, Howard B Rosen, Orbimed Advisors Llc and Ra Capital Healthcare Fund Lp. View Insider Buying and Selling for Kala Pharmaceuticals.

How do I buy shares of Kala Pharmaceuticals?

Shares of KALA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Kala Pharmaceuticals' stock price today?

One share of KALA stock can currently be purchased for approximately $4.58.

How big of a company is Kala Pharmaceuticals?

Kala Pharmaceuticals has a market capitalization of $155.77 million. The company earns $-66,740,000.00 in net income (profit) each year or ($2.48) on an earnings per share basis. Kala Pharmaceuticals employs 130 workers across the globe.View Additional Information About Kala Pharmaceuticals.

What is Kala Pharmaceuticals' official website?

The official website for Kala Pharmaceuticals is http://www.kalarx.com/.

How can I contact Kala Pharmaceuticals?

Kala Pharmaceuticals' mailing address is 490 ARSENAL WAY SUITE 120, WALTHAM MA, 02453. The company can be reached via phone at 781-996-5252 or via email at [email protected]


MarketBeat Community Rating for Kala Pharmaceuticals (NASDAQ KALA)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  196 (Vote Outperform)
Underperform Votes:  201 (Vote Underperform)
Total Votes:  397
MarketBeat's community ratings are surveys of what our community members think about Kala Pharmaceuticals and other stocks. Vote "Outperform" if you believe KALA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KALA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel